Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

https://doi.org/10.1136/bmjopen-2023-073055

Published in:
BMJ Open

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2023 The Authors.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback
Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Jiayan Chen 1,1, Guanghao Qin 1,1, Liangzhe Li 1,1, Yifan Qi 1,1, Huixin Che 1,1, He Huang 1,1, Yang Xia 1,1, Qing Zhang 2,2, Yi Wu 3,3, Lanting Yang 4,4, Salissou Moutari 5,5, Jonathan E Moore 6,6, Ling Xu 1,1, Wei He 1,1, Sile Yu 1,1,7 Emmanuel Eric Pazo 1,1, Xingru He 1,1,7

ABSTRACT

Introduction Evaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found to be beneficial in reducing signs and symptoms of dry eye.

Methods and analysis A randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol ophthalmic solution eye-drops) and IPL+ group (IPL combined with 3% diquafosol eye-drops). All groups will be followed up for 4 weeks. The primary outcome measures will be the non-invasive tear break-up time and the Ocular Surface Disease Index change from the baseline. The secondary outcome measures will include conjunctival and cornea staining with fluorescein and lissamine, meibomian gland function and secretion quality, tear film lipid layer score, tear meniscus height, conjunctival hyperemia (redness score) changes. Adverse events also will be monitored and documented.

Discussion This study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active control group) in participants with EDE.

Ethics and dissemination Management of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study’s findings will be shared regardless of the effect’s direction.

Trial registration number NCT05694026.

INTRODUCTION

Background and rationale Evaporative dry eye (EDE) has been reported to be the most prevalent form of dry eye disease (DED), 1-5 which is primarily caused by meibomian gland hypofunction or meibomian gland dysfunction (MGD). 4-6 MGD can be chronic or diffused anomaly of the meibomian glands, often characterised by terminal duct blockage and qualitative/quantitative alterations in glandular secretion. 7 The International Workshop on MGD can be chronic or diffused anomaly of the meibomian glands, often characterised by terminal duct blockage and qualitative/quantitative alterations in glandular secretion ‘b’ the International Workshop on MGD. 7 These glands are modified sebaceous glands that release meibum directly onto the ocular surface. Signs and symptoms of EDE and MGD can be addressed by improving the quality and quantity of meibum secretion. 8

Diquafosol tetrasodium (DQS) topical ophthalmic solution is a dinucleotide polyphosphate which is a purinoceptor agonist; when administered to the ocular surface, it binds to P2Y2 receptors and stimulates mucin and tear secretion. 9-11 It also improves the tear film composition and stability. 12-14 It has a corneal epithelial-repairing effect and can be used to treat ocular surface damage caused by meibomian gland dysfunction.
by dry eye. By targeting the inflammation involved in the pathogenesis of dry eye, it can inhibit the expression of inflammatory pathways and inflammatory factors that are involved in the pathogenesis of dry eye. The safety and benefits of DQS in improving dry eye signs and symptoms have been demonstrated in randomised clinical trials. At present, DQS is clinically available as a 3% ophthalmic solution (Diquas, Santen) which, due to rapid ocular clearance, requires frequent administration (six times/day).

Intense pulsed light (IPL) is widely used to treat dermatological conditions, and its non-coherent polychromatic light source with a wide wavelength range of 500–1200 nm has been reported to stimulate facial sebaceous glands. The photothermal effect of IPL is postulated to relieve inflammation by removing aberrant surface microvasculature and enhancing meibomian gland function. Furthermore, an increase in fibroblast proliferation, collagen formation and local blood flow has been associated with the application of IPL on the skin. Several studies including Toyos et al and Martinez-Hergueta et al have evaluated the safety and benefits of IPL therapy for improving signs of DED and combined it with other therapies such as heated eye mask (HEM) 0.1% sodium hyaluronate eye-drops and blood extract eye-drops. Therefore, a randomised controlled trial (RCT) is warranted to assess the safety and efficacy of combining IPL with DQS for patients suffering from DED.

Objectives
The primary objective of this study is to assess whether the combination of IPL with 3% diquafosol ophthalmic solution is more effective than IPL and 3% diquafosol ophthalmic solution in alleviating signs and symptoms of DED.

Trial design
This is a prospective, RCT performed at He Eye Specialist Hospital (HESH) (ethics approval number: IRB (2022) K029.01). The study adheres to the tenets of the Declaration of Helsinki and is registered at ClinicalTrials.gov (NCT05694026) using the Standard Protocol Items: Recommendations for Interventional Trials reporting guidelines. Randomisation will be performed using a web-based, online, sealed envelope-based system (https://www.sealedenvelope.com). Specific study information sheets will be provided to patients prior to taking consent. Following a dedicated screening and randomisation visit for eligible patients, participants will be randomised to one of three trial arms.

METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES
Study setting
This study will be conducted between 1 March 2023 and 30 November 2023. Participants will be recruited at the Department of Ophthalmology, HESH.

Patient and public involvement
Patients and the public will not be involved in the design, implementation, reporting or dissemination plans of this study.

Eligibility criteria
Inclusion criteria
1. Age ≥18 years.
2. Consenting participants.
3. Able and willing to comply with the treatment/follow-up schedule.
4. Bilateral signs and symptoms of DED: (1) Ocular Surface Disease Index (OSDI) questionnaire ≥13, (2) non-invasive tear break-up (NITBUT) ≤5s and (3) conjunctival staining score (CS) ≥3 points. The presence of two or more criteria was used to establish a positive DE diagnosis based on the 2016 Asia Dry Eye Society criteria.

Exclusion criteria
1. A recent history (past 30 days) of topical ophthalmic medication use, including antibiotics, steroids, non-steroidal anti-inflammatory drugs or required the chronic use of topical ophthalmic medications.
2. Eyelids or intraocular tumours.
3. Active allergy or infection, or inflammatory disease that may prevent the subjects from completing the study at the ocular surface.
4. Any structural changes in the lacrimal passage.
5. Glaucoma.
6. Diabetes or other systemic, dermatological or neurological diseases that affect the health of the ocular surface.
7. Use of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as antianxiety, antidepressive and antihistamine medications, within 3 months.
8. Pregnant or breast feeding.
9. Contact lenses wearers.

Informed consent
Trained and experienced clinicians will seek informed permission from prospective participants.

Additional consent provisions for collection and use of participant data and biological specimens
This trial does not involve collecting biological specimens.

Interventions
The explanation for the choice of comparators
After enrolment in the study, treatments will be initiated immediately after randomisation. Participants in the DQS group and IPL+ group will use one drop of 3% DQS (Diquas; Santen Pharmaceutical, Osaka, Japan) six times per day for 4 weeks (28 days), whereas participants in the IPL+ group and IPL group will undergo two IPL treatment sessions of M22 (Lumenis, Yokneam, Israel) IPL system, 2 weeks apart. IPL treatment uses a non-coherent chromatic light source with a wide wavelength range of 500–1200 nm has been reported to stimulate facial sebaceous glands. The photothermal effect of IPL is postulated to relieve inflammation by removing aberrant surface microvasculature and enhancing meibomian gland function. Furthermore, an increase in fibroblast proliferation, collagen formation and local blood flow has been associated with the application of IPL on the skin. Several studies including Toyos et al and Martinez-Hergueta et al have evaluated the safety and benefits of IPL therapy for improving signs of DED and combined it with other therapies such as heated eye mask (HEM) 0.1% sodium hyaluronate eye-drops and blood extract eye-drops. Therefore, a randomised controlled trial (RCT) is warranted to assess the safety and efficacy of combining IPL with DQS for patients suffering from DED.

Objectives
The primary objective of this study is to assess whether the combination of IPL with 3% diquafosol ophthalmic solution is more effective than IPL and 3% diquafosol ophthalmic solution in alleviating signs and symptoms of DED.
polychromatic light source with a wavelength spectrum of 500–1200 nm on the cutaneous facial sebaceous glands.

**Intervention description**

In this study, patients receive either DQS, IPL or IPL combined with DQS for 4 weeks based on the group they are placed in. Two follow-up visits will be performed at week 2 and week 4 in all groups; comprehensive eye examinations will be conducted by an ophthalmologist, including primary outcomes, secondary outcomes and safety evaluation.

**Criteria for discontinuing or modifying allocated interventions**

If dry eye signs and symptoms worsen, participants will be stopped and advised to use the designated device. Adverse events (AEs) will be continuously monitored. In case of an AE, participants will be informed about the severity of the event, and principal investigator (PI) will decide if participants can continue further. If participants consent and agree, they will be reminded daily regarding the administration of eye-drops, recording their exposure to mobile telephones or computer time, and any queries regarding the study will be answered by trained clinical staff at HESH.

**Strategies to improve adherence to interventions**

Participants will be reminded by phone and email every week, and then appointments will be scheduled in advance according to their availability time. In order to improve adherence, patients will be given a medication record booklet, and their medication status will be checked at each follow-up visit. In the event of non-compliance, such as absence, participants will be contacted by phone or email to ask if they will continue or terminate the study early.

**Relevant concomitant care permitted or prohibited during the trial**

Any other dry eye systemic or topical medication, treatment, or therapy will be prohibited during the course of this study.

**Provisions for post-trial care**

There is no anticipated harm and compensation for trial participation, but participants who show signs and symptoms of deterioration in their dry eye status will be directed to their local dry eye centre for further treatment.

**Outcomes**

All patients will be assessed at baseline, 14 and 28 days. We plan to use primary and secondary outcomes measures, symptoms, and corneal and meibomian gland improvement will be compared between the three groups.

**Primary outcome**

OSDI: OSDI is a questionnaire consisting of 12 questions for evaluating the effects of dry eye syndrome on vision, ocular symptoms and any condition associated with DED. The patient will answer each question on a scale ranging from 0 to 4, with ‘0’ indicating ‘none of the time’ and ‘4’ indicating ‘all of the time.’ If a particular question is deemed irrelevant, it will be marked as ‘not applicable’ and excluded from the analysis. The OSDI total score is calculated according to the following formula. The total score ranges from 0 to 100, with higher scores representing more severe cases of DED symptoms.

NITBUT: The Keratograph 5M (Oculus, Germany) topographer will measure non-invasive tear breaking time. Three sequential readings will be captured, the median value will be included in the final analysis, and the median value will be recorded.

**Secondary outcomes**

Fluorescein and lissamine conjunctival and cornea staining: Fluorescein and lissamine staining (CS) of the ocular surface will be divided into three zones comprising nasal conjunctival, corneal and temporal conjunctival areas. The staining score ranged from 0 to 3 for each zone, yielding a total score of 0–9 for the ocular surface.

Tear meniscus height: Tear meniscus height (TMH) using the Keratograph 5M (Oculus, Germany) topographer will be measured three times consecutively, and the median value was recorded.

Conjunctival hyperaemia: Conjunctival hyperaemia (RS score) will be assessed by Keratograph image (Oculus, Germany) of 1156×873 pixels. RS (accurate to 0.1 U) was displayed on the computer screen that ranged from 0.0 (normal) to 4.0 (severe).

Meibomian gland function and secretion quality: Meibum quality will be assessed under a slit-lamp. Eight meibomian glands in the middle parts of the eyelid will be evaluated using a scale of 0–3 for each gland (0 represented clear meibum; 1 represented cloudy meibum; 2 represented cloudy and granular meibum and 3 means thick, toothpaste-like consistency meibum).

Tear Film Lipid Layer Score: The interferometry patterns will be assessed using DR-1 (Kowa, Nagoya, Japan). The results will be graded as follows: grade 1, somewhat grey colour, uniform distribution; grade 2, rather grey colour, non-uniform distribution; grade 3, a few colours, non-uniform distribution; grade 4, many colours, non-uniform distribution; grade 5, corneal surface partially exposed.

**Participant timeline**

The schedule for data collection and visits is shown in table 1. After registration for this study, the assigned treatment intervention will be administered for 4 weeks. Furthermore, the effect will be examined during the 2-week follow-up period of 4 weeks (figure 1).

**Sample size**

The sample size calculation is based on the primary outcome measures, namely NITBUT and OSDI scores, to establish the non-inferiority of the IPL+ group compared with IPL group and DQS group in terms of the changes in the mean from the baseline in OSDI score at day 28. For the NITBUT scores, a sample size of 106 is sufficient to
participants blinded to the treatment assignment. This clinical study will be done in a single site, with recruitment summarised.

- Using descriptive statistics, safety data will be conducted using an analysis of variance. Using paired t-tests, within-treatment differences. Using two-way analysis of variance that will account for treatment and baseline OSDI score stratification to compare treatment.

- For the detection of clinically significant difference of 1.2 between the IPL+ group and either of the two other groups (IPL group and DQS group) while assuming a SD of 1.15, the required sample size is max (106, 98)=106 in each group.

- With the inclusion of the multidose treatment groups and a drop-out rate of 8%, it is estimated that about 350 individuals. Therefore 360 individuals will be enrolled, 120 in each group. The intended-to-treat population will be randomly allocated to the three groups.

- The primary and secondary efficacy analyses will use a two-way analysis of variance that will account for treatment and baseline OSDI score stratification to compare treatment differences. Using paired t-tests, within-treatment differences from baseline will be evaluated (alpha level 0.05). Additional analyses of OSDI subgroups and questionnaire data will be conducted using an analysis of variance. Using descriptive statistics, safety data will be summarised.

**Recruitment**

This clinical study will be done in a single site, with participants blinded to the treatment assignment. This research is open to patients diagnosed with DED at HESH’s Department of Ophthalmology. Participants will be recruited using adverts in the distribution pamphlets, the website and social media postings. Each participant’s demographic information (including ocular diseases and current/previous usage of drugs and/or lubricating eye-drops) will be collected during the first (screening) appointment. Participants will not be limited based on age, sex or ethnicity (table 2).

**Assignment of interventions: allocation**

**Sequence generation**

A web-based randomisation application will be used (https://www.project-redcap.org/). Participants will be randomised by simple randomisation process. Allocation will be carried out using block randomisation and stratified according to age (allocation factor: age <80 years or ≥80 years) (known only to the statistical team, not stated here to maintain masking). Participants will be in a 1:1:1 allocation ratio to IPL group, DQS group or IPL+ group.

**Concealment mechanism**

The block size will be concealed from other researchers, and the randomisation table will not be available for assessment by anyone else involved in the study. Randomisation will be performed by an independent biostatistician. The biostatistician is the only one who has access to check the file. The allocation list will be kept in a separate file on a different computer.

**Implementation**

Random allocation will be conducted after the enrolment. Random numbers with corresponding participants will be determined in the order of the time of the first visit and divided into three groups (IPL+, IPL or DQS group). The allocation result will not be announced to the participants until the end of the data collection phase of the trial. Researchers collecting and analysing data related to this trial will be blinded to the participant allocation results.

**Assignment of interventions**

**Blinding**

The treatment assignment for the study will be triple-masked. Participants in the research would be unable to recognise the contents. A masked examiner for all clinical assessments will not be involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the three groups. Participants will be randomly assigned to one of the three treatment groups, and they will undergo IPL treatment with 12 homogeneously spaced pulsed light to both eyes and a sham treatment to both eyes. The box containing ampoules will be labelled with a batch number, including the study reference number, participant ID, contact number, investigator name, site address, the expiration date of the eye-drops, storage instructions and a statement informing the participant that the eye-drops are for use only in clinical trials and should not be ingested. The

| Items Baseline 2 weeks 4 weeks |
|-----------------------------|------------------|
| Informed consent     | ✓                |
| Patient background    | ✓                |
| Ocular Surface Disease Index scores | ✓ | ✓ | ✓ |
| IOP                 | ✓ | ✓ | ✓ |
| BCVA                | ✓ | ✓ | ✓ |
| Non-invasive tear break-up | ✓ | ✓ | ✓ |
| Conjunctival and cornea fluorescent staining | ✓ | ✓ | ✓ |
| Tear Film Lipid Layer Score | ✓ | ✓ | ✓ |
| Corneal endothelial cells | ✓ | ✓ | ✓ |
| Tear meniscus height | ✓ | ✓ | ✓ |
| Conjunctival hyperaemia | ✓ | ✓ | ✓ |
| Meibomian gland function | ✓ | ✓ | ✓ |
| Meibomian secretion quality | ✓ | ✓ | ✓ |
| Adverse event        | ✓ | ✓ | ✓ |

**Patient background, including date of birth, sex, race, ethnicity and allergy history.**

**BCVA, best-corrected visual acuity; IOP, intraocular pressure.**
circumstances and procedures under which unblinding is permissible will be determined and performed by the PI.

**Procedure for unblinding if needed**
The PI will determine and perform the circumstances and procedures under which unblinding is permissible.

**Participant withdrawal**
Based on the following criteria, patients will be removed from the research.
1. When it is deemed challenging to continue the study owing to the emergence of new ailments.
2. When the research participant cannot be located.
3. In the case of pregnancy or pregnancy suspicion.
4. When participants or their legal guardians want to end their participation in a study.
5. When the participant’s caretaker cannot guarantee their participation in the study.
6. When the research project is concluded.
7. When the lead investigator and subinvestigators believe that it is acceptable to cease the study for reasons other than those listed above.

**Data collection and management**

**Plans for assessment and collection of outcomes**
Data administration is the responsibility of Jiayan Chen, HESH, Department of Clinical Research, as chosen by the PI (Emmanuel Eric Pazo). This research will collect data using a proprietary EMR case report form and management application. Following database lock, the individual responsible for the statistical analysis will get the locked data following the database. The data management handbook will provide the details on any specific information. At the end of the study, a report

---

**Figure 1** Study flow chart. DQS, diquafosol; IPL, intense pulsed light.
on the implementation and the status of data management will be compiled and sent to the PI with the locked research data.

**Plans to promote participant retention and complete follow-up**
Informed consent will include information regarding follow-up assessments for all participants. In the event of participants discontinuing or deviating from intervention protocols, the study team will initiate contact and prioritise addressing any concerns that may be impacting their adherence to the intervention protocols. If these concerns cannot be resolved, the participants will be requested to complete subsequent self-assessment questionnaires online.

Data will be gathered during prerandomisation, termination and follow-up periods at 2 and 4 weeks. The method of data collection for this study will involve the use of clinical tests and self-report questionnaires, which will be administered through an online platform. In order to guarantee the completeness and accuracy of the gathered data, the online questionnaires will be encoded in a manner that necessitates respondents to provide comprehensive responses to all inquiries prior to submitting their answers.

**Data management**
Data collection and data entry were performed by separate experienced staff members at HESH, Department of Clinical Research. Supervision and double confirmation were performed by Jiayan Chen, along with weekly backup, to ensure data quality.

**Confidentiality**
Each participant’s personal information will be kept confidential in the same way as their medical histories in the hospital before, during and after the trial.

**Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use**
Not applicable: There will be no biological specimens collected.

**Statistical methods**
**Statistical methods for primary and secondary outcomes**
The software Statistical Analysis in Social Sciences (SPSS, V.26, IBM) for MacOS software will be used to analyse the data. Data from both eyes will be collected for all patients participating in the treatment at the following stages: baseline, first follow-up at week 2 and second follow-up at week 4. Repeated measures analysis will be used to compare comparisons across time periods, while paired analyses will be used to compare pretreatment and post-treatment data at specific time periods. The Kolmogorov-Smirnoff test will be used to determine the normality of variables. The background of the subjects will be tabulated by calculating the mean and SD for continuous variables and the frequency and percentage for categorical variables. Analysis of variance will be used to analyse ordinal variables and those having non-normal distributions. The primary outcome measures for this study are NITBUT and OSDI scores before and after treatment. For the primary endpoint, between-group comparisons using baseline as a covariate and an analysis of covariance will be performed to estimate the adjusted mean, its 95% CI and the p value.

**Interim analyses**
Not applicable: No anticipated problems are detrimental to the participant, so interim analysis is not warranted.

**Methods for additional analyses (e.g., subgroup analyses)**
Subgroup analyses are not planned for this study.

---

**Table 2** The schedule of enrolment, interventions and assessments of this trial

<table>
<thead>
<tr>
<th>Time point</th>
<th>Study period</th>
<th>Enrolment</th>
<th>Allocation</th>
<th>Postallocation</th>
<th>Close-out</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2023</td>
<td>2023</td>
<td>Day 0</td>
<td>Day 14</td>
<td>Day 28</td>
<td>End-2023</td>
</tr>
</tbody>
</table>

Enrolment:
- Eligibility screen X
- Informed consent X

Allocation X

Interventions:
- (IPL+DQS)
- (DQS)
- (IPL) X X

Assessments:
- (The baseline variables) X X
- (The primary outcome) X X X
- (The second outcome) X X X

DQS, diquafosol; IPL, intense pulsed light.
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data

After accounting for lost to follow-up and missing data in sample size calculations. Using a two-tailed t-test of difference between means with a power of 80% and a significance level of 5%, we allowed for a drop-out rate of 10%, using an additional 10% to compensate for potential deviations of dry eye measures from the normal distribution.

Plans to give access to the complete protocol, participant-level data and statistical code

The datasets analysed during the current study and statistical code are available from the corresponding author on reasonable request, as is the complete protocol.

Oversight and monitoring
Composition of the coordinating centre and trial steering committee

The subject leader and the project manager will form the steering committee (SC). The SC is accountable for managing the whole project. The monitor group’s (MG) inspectors are appointed by the SC. The MG will oversee the entire research procedure in compliance with the GCP requirements. The inspector will analyse the investigator’s adherence to the protocol, the protection of participants’ rights and interests, the quality of the CRF form, and the investigators’ understanding of different standards before submitting inspection reports to the SC.

Composition of the data monitoring committee, its role and reporting structure

Due to the projected low frequency of AEs and the modest numbers in each location, no data monitoring committee has been convened for this trial. The database will be constructed using Excel (Microsoft, USA 2022 version), and regular data monitoring will be undertaken in accordance with the sponsor’s standard operating procedures. The SC will have oversight and access to the trial under the supervision of the trial manager at any time during the study.

AE reporting and harms

AEs are unanticipated indications, symptoms or illnesses seen during a clinical study, regardless of their relationship to the treatment. There may be local, general and psychological unwanted effects (table 3). If any discomfort or new changes in condition during the study period, or any unexpected situation, whether related to the study or not, one should promptly notify the doctor, who will make a judgement and give appropriate medical treatment. At the end of each examination, the doctor will evaluate eye health status according to the examination results. If the condition deteriorates or is no longer suitable for the study, the study may be terminated early. At the same time, the doctor will provide other treatment options that are more suitable for the current situation to ensure health to the greatest extent. If major AEs occur, HESH Certified Review Board will be notified; experimental treatments will be discontinued promptly, and appropriate therapies will be offered.

Frequency and plans for auditing trial conduct

The study will be reviewed and evaluated weekly by an independent supervisor not related to the PI and sponsors.

Plans for communicating significant protocol amendments to relevant parties (eg, trial participants, ethical committees)

If there are modifications to eligibility criteria, outcomes or analyses, a revised protocol will be submitted for approval to the HESH Medical Ethics Committee.

Dissemination plans

The study’s findings will be shared regardless of the effect’s direction. All possible beneficiaries of the research, including patients, caretakers, family, doctors, advisory boards and medical boards, will receive trial data. Publications in high-impact, open-access medical journals and talks at national and international medical conferences will serve this purpose.

**DISCUSSION**

DQ8 stimulates P2Y\textsubscript{1} receptors on the ocular surface, which enhances the secretion of water and secretory mucin from conjunctival tissue. At present, multicentre clinical trials have proved the advantages and efficacy of diquafosol sodium drops in the treatment of dry eyes, and the Asian Dry Eye Workshop identifies it as the current first-choice treatment for aqueous tear deficiency dry eyes and as one of the first choices for the treatment of mucin deficiency dry eyes. The primary untoward effects observed were ocular discharge, ocular irritation, and ocular pain; however, these manifestations resolved within a period of 28 days. These events will be assessed and mentored continually during the study and follow-up phase of the study.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Possible adverse events and solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse events</strong></td>
<td><strong>Solutions</strong></td>
</tr>
<tr>
<td>Visual discomfort</td>
<td>Standard operation</td>
</tr>
<tr>
<td>Eye irritation, conjunctival hyperaemia, eye pain</td>
<td>No special treatment was required, relieve and subside within 1–3 days</td>
</tr>
<tr>
<td>Periocular swelling</td>
<td>Resolve within a few hours</td>
</tr>
<tr>
<td>Bluish-purple bruise (purpura)</td>
<td>Rare cases may last from five to fifteen days; no special treatment is required</td>
</tr>
<tr>
<td>The skin around the eye becomes sensitive and fragile</td>
<td>Avoiding makeup and rubbing</td>
</tr>
<tr>
<td>Burn injury occurs</td>
<td>In rare cases, follow instructions</td>
</tr>
<tr>
<td>Allergy, abnormal sensation in the eye, etc.</td>
<td>Excluded and treatment</td>
</tr>
</tbody>
</table>
Literature review shows that IPL is a relatively new method for the treatment of lipid-abnormal dry eye caused by MGD. IPL can relieve the symptoms and signs of MGD-related dry eye by reducing eyelid inflammation, thermal effect, sterilisation, acarasis and light regulation.\textsuperscript{55, 56} With respect to the adverse effects, the majority of studies have reported that participants did not experience any significant negative effects, apart from temporary occurrences of erythema, oedema and pain. Nevertheless, the likelihood of hyperpigmentation, blisters and a burning sensation cannot be ruled out in certain instances, particularly in patients with darker skin phototypes.\textsuperscript{57} Potential corneal and/or retinal toxicity will be assessed and monitored continuously. Therefore, this study aims to assess the effectiveness of the combination of IPL with 3\% DQS ophthalmic solution, providing more options for treatment. In future studies, we will further expand the sample size and conduct a deeper analysis of the mechanism of symptom improvement in the hope of providing clinicians with more treatment options.

**Trial status**

Recruitment began in March 2023, and the approximate date when recruitment will be completed is November 2023. Protocol version 2.0 was approved on January 2023.

**Author affiliations**

1Department of Ophthalmology, He Eye Specialist Hospital, Shenyang, China

2Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, China

3Department of Ophthalmology, China Medical University Second Hospital, Shenyang, China

4Department of Ophthalmology, Wenzhou Medical University Eye Hospital, Wenzhou, China

5School of Mathematics and Physics, Queen’s University Belfast, Belfast, UK

6Department of Ophthalmology, Cathedral Eye Clinic, Belfast, UK

7School of Public Health, He University, Shenyang, China

**Acknowledgements**

The authors would like to express their appreciation for the effort of all personnel involved in this trial.

**Contributors**

Conception and design of the research: JC, GG, LL, YG, HC, HH, YX, OZ, YW, LY, SM, JM, LX, WH, SY, XH and EEP.

Analysis and interpretation of the data: JC, GG and EEP.

Writing original draft preparation: JC.

Critical revision of the manuscript: YX, QZ, YW, LY, SM, JM, LX, WH, SY, XH and EEP.

Analysis and interpretation of the data: JC.

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Jiayan Chen http://orcid.org/0000-0002-3425-8486

Guanghao Qin http://orcid.org/0000-0003-1596-7970

Liangzhe Li http://orcid.org/0000-0002-3620-9805

Yifan Qi http://orcid.org/0000-0001-7750-6729

Huixin Che http://orcid.org/0000-0002-7777-6777

He Huang http://orcid.org/0000-0002-7777-6777

Yang Xia http://orcid.org/0000-0002-7777-6777

Qing Zhang http://orcid.org/0000-0002-7777-6777

Yi Wu http://orcid.org/0000-0002-6163-6737

Lanting Yang http://orcid.org/0000-0002-9723-3972

Salissiu Moutari http://orcid.org/0000-0002-9723-3972

Ling Xu http://orcid.org/0000-0002-8024-1263

Wei He http://orcid.org/0000-0002-8024-1263

Sile Yu http://orcid.org/0000-0002-9956-2526

Emmanuel Eric Pazo http://orcid.org/0000-0002-0848-827X

Xingru He http://orcid.org/0000-0002-4180-9290

**REFERENCES**


